RT Journal Article
SR Electronic
T1 Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.28.22276983
DO 10.1101/2022.06.28.22276983
A1 Davies, Mary-Ann
A1 Morden, Erna
A1 Rosseau, Petro
A1 Arendse, Juanita
A1 Bam, Jamy-Lee
A1 Boloko, Linda
A1 Cloete, Keith
A1 Cohen, Cheryl
A1 Chetty, Nicole
A1 Dane, Pierre
A1 Heekes, Alexa
A1 Hsiao, Nei-Yuan
A1 Hunter, Mehreen
A1 Hussey, Hannah
A1 Jacobs, Theuns
A1 Jassat, Waasila
A1 Kariem, Saadiq
A1 Kassanjee, Reshma
A1 Laenen, Inneke
A1 Roux, Sue Le
A1 Lessells, Richard
A1 Mahomed, Hassan
A1 Maughan, Deborah
A1 Meintjes, Graeme
A1 Mendelson, Marc
A1 Mnguni, Ayanda
A1 Moodley, Melvin
A1 Murie, Katy
A1 Naude, Jonathan
A1 Ntusi, Ntobeko A. B.
A1 Paleker, Masudah
A1 Parker, Arifa
A1 Pienaar, David
A1 Preiser, Wolfgang
A1 Prozesky, Hans
A1 Raubenheimer, Peter
A1 Rossouw, Liezel
A1 Schrueder, Neshaad
A1 Smith, Barry
A1 Smith, Mariette
A1 Solomon, Wesley
A1 Symons, Greg
A1 Taljaard, Jantjie
A1 Wasserman, Sean
A1 Wilkinson, Robert J.
A1 Wolmarans, Milani
A1 Wolter, Nicole
A1 Boulle, Andrew
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/06/28/2022.06.28.22276983.abstract
AB Objective We aimed to compare clinical severity of Omicron BA.4/BA.5 infection with BA.1 and earlier variant infections among laboratory-confirmed SARS-CoV-2 cases in the Western Cape, South Africa, using timing of infection to infer the lineage/variant causing infection.Methods We included public sector patients aged ≥20 years with laboratory-confirmed COVID-19 between 1-21 May 2022 (BA.4/BA.5 wave) and equivalent prior wave periods. We compared the risk between waves of (i) death and (ii) severe hospitalization/death (all within 21 days of diagnosis) using Cox regression adjusted for demographics, comorbidities, admission pressure, vaccination and prior infection.Results Among 3,793 patients from the BA.4/BA.5 wave and 190,836 patients from previous waves the risk of severe hospitalization/death was similar in the BA.4/BA.5 and BA.1 waves (adjusted hazard ratio (aHR) 1.01; 95% confidence interval (CI) 0.92; 1.12). Both Omicron waves had lower risk of severe outcomes than previous waves. Prior infection (aHR 0.19, 95% CI 0.16; 0.22) and vaccination (aHR 0.24; 95% CI 0.15; 0.39 for boosted vs. no vaccine) were protective.Conclusion Disease severity was similar amongst diagnosed COVID-19 cases in the BA.4/BA.5 and BA.1 periods in the context of growing immunity against SARS-CoV-2 due to prior infection and vaccination, both of which were strongly protective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding for the Western Cape Provincial Health Data Centre from the Western Cape Department of Health, the US National Institutes for Health (R01 HD080465, U01 AI069924), the Bill and Melinda Gates Foundation (1164272, 1191327), the United States Agency for International Development (72067418CA00023), the European Union (101045989) and the Grand Challenges ICODA pilot initiative delivered by Health Data Research UK and funded by the Bill & Melinda Gates and Minderoo Foundations (INV-017293). Funding was also received from Wellcome (203135/Z/16/Z [RJW, GM, WCPHDC], 222574 [RJW, WCPHDC] 214321/Z/18/Z [GM]) and the Medical Research Council of South Africa (RJW, MAD). RJW additionally receives support from the Francis Crick Institute which is funded by Wellcome (FC0010218), MRC (UK) (FC0010218), and Cancer Research UK (FC0010218). GM is also funded by the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa (Grant No 64787). The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The opinions, findings and conclusions expressed in this manuscript reflect those of the authors alone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Cape Town and Stellenbosch University Health Research Ethics Committees and Western Cape Government: Health. Individual informed consent requirement was waived for this secondary analysis of de-identified data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe underlying data are de-identified pseudo-anonymised routine patient records for which patients have not consented to their de-identified data being part of publicly accessible repositories with inherent risks of re-identification. The Western Cape Department of Health and Wellness evaluates research proposals for all research in the public health sector in the Province, including those which draw on similar datasets to the current study, based on routine data, subject to standard research ethics, government approval and data governance prescripts.